Cellebrite DI Ltd. cash flow to debt ratio of 745.30% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Cellebrite DI Ltd.'s free cash flow has increased 28.11% from $121.56M last year to $155.73M, signaling increasing performance

Cellebrite DI Ltd.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Cellebrite DI Ltd.'s debt has increased relative to shareholder equity from 0.03 last year to 0.04 today, signaling weakened financials

Cellebrite DI Ltd. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Cellebrite DI Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Cellebrite DI Ltd.'s profit margin has increased (-120.52%) in the last year from -70.54% to 14.48%, signaling increasing performance

Cellebrite DI Ltd.'s short-term assets of $575.85M exceed its short-term liabilities of $369.66M

Cellebrite DI Ltd.'s return on assets of 7.55% is higher than the 5.00% threshold, indicating efficient asset utilization

Cellebrite DI Ltd.'s return on equity of 15.53%, is higher than 15.00%, indicating good performance

Cellebrite DI Ltd.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Cellebrite DI Ltd. had positive net income in 3.00 out of 5 years, indicating stable and consistent earnings

Cellebrite DI Ltd. has positive free cash flow, indicating the company generates cash after capital expenditures

Cellebrite DI Ltd. has a free cash flow yield of 4.54%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Cellebrite DI Ltd.'s yearly earnings has increased -127.68% since last year from $-283.01M to $78.33M, signaling increasing performance

Cellebrite DI Ltd.'s yearly revenue has increased 18.56% since last year from $401.20M to $475.68M, signaling increasing performance

ROIC 8.83% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Cellebrite DI Ltd.'s 3-year revenue CAGR of 20.68% is positive, indicating growing revenue over the past 3 years

Cellebrite DI Ltd. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Cellebrite DI Ltd. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Cellebrite DI Ltd. is overvalued relative to its fair value price of 11.50 based on Discounted Cash Flow model

Cellebrite DI Ltd. has an earnings yield of 2.12%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Cellebrite DI Ltd. is overvalued relative to its fair value price of 2.61 based on EBITDA multiple model

Cellebrite DI Ltd. has an EV/EBITDA ratio of 26.03x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Cellebrite DI Ltd. is overvalued relative to its fair value price of 3.97 based on Earnings Fair Value model

Cellebrite DI Ltd. has a PEG-ratio under 1 which is considered undervalued

Cellebrite DI Ltd. has a price-to-book ratio of 6.64x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Cellebrite DI Ltd. has a price-to-sales ratio of 6.91x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue